CA3200691A1 - A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections - Google Patents

A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Info

Publication number
CA3200691A1
CA3200691A1 CA3200691A CA3200691A CA3200691A1 CA 3200691 A1 CA3200691 A1 CA 3200691A1 CA 3200691 A CA3200691 A CA 3200691A CA 3200691 A CA3200691 A CA 3200691A CA 3200691 A1 CA3200691 A1 CA 3200691A1
Authority
CA
Canada
Prior art keywords
aat
composition
pharmaceutical composition
protein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3200691A
Other languages
English (en)
French (fr)
Inventor
Manfred Stangl
Michael Strassmair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aatec Medical GmbH
Original Assignee
Aatec Medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20206287.3A external-priority patent/EP3995130A1/en
Application filed by Aatec Medical GmbH filed Critical Aatec Medical GmbH
Publication of CA3200691A1 publication Critical patent/CA3200691A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3200691A 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections Pending CA3200691A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20206287.3 2020-11-06
EP20206287.3A EP3995130A1 (en) 2020-11-06 2020-11-06 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP21159620 2021-02-26
EP21159620.0 2021-02-26
PCT/EP2021/080936 WO2022096708A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Publications (1)

Publication Number Publication Date
CA3200691A1 true CA3200691A1 (en) 2022-05-12

Family

ID=78806458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3200691A Pending CA3200691A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Country Status (7)

Country Link
US (1) US20230414730A1 (https=)
EP (1) EP4240323A1 (https=)
JP (1) JP2023547728A (https=)
AU (1) AU2021375735A1 (https=)
CA (1) CA3200691A1 (https=)
IL (1) IL302649A (https=)
WO (1) WO2022096708A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN115381857B (zh) * 2022-10-28 2023-02-03 上海市东方医院（同济大学附属东方医院） 间充质干细胞在制备治疗hpv持续感染的药物中的应用
EP4680254A1 (en) * 2023-03-17 2026-01-21 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025227013A1 (en) * 2024-04-26 2025-10-30 Musc Foundation For Research Development Extracellular vesicles from alpha-1 antitrypsin overexpressing cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
EP1366175B1 (en) * 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP2148693A4 (en) * 2007-04-20 2010-06-02 Univ Colorado ALPHA-I-ANTITRYPINE WITHOUT SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY
RU2539099C2 (ru) 2009-04-13 2015-01-10 Апцет Гмбх Унд Ко.Кг Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
US9901600B2 (en) * 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Also Published As

Publication number Publication date
JP2023547728A (ja) 2023-11-13
AU2021375735A9 (en) 2024-09-05
US20230414730A1 (en) 2023-12-28
EP4240323A1 (en) 2023-09-13
AU2021375735A1 (en) 2023-06-08
IL302649A (en) 2023-07-01
WO2022096708A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
US20230414730A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
Pocsfalvi et al. COVID-19 and extracellular vesicles: an intriguing interplay
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染
JP2017505348A (ja) 肺疾患治療のための肥満細胞安定剤
WO2019046664A1 (en) COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS
US20260116934A1 (en) Compositions and Methods for Delivering CFTR Polypeptides
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2023527791A (ja) ウイルス性呼吸器感染症を治療するための方法
KR20220134764A (ko) 염증성 폐 질환의 흡입식 치료를 위한 인간 항염증성 펩타이드
US20210189427A1 (en) Compositions and methods for gene delivery to the airways and/or lungs
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US20260000791A1 (en) In vivo gene therapy using intraosseous delivery of a lentiviral gene construct
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
WO2011110861A2 (en) Therapy for influenza like illness
KR20210097756A (ko) 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
Zhang et al. Adipose-derived mesenchymal stem cells suppress ozone-mediated airway inflammation in a mouse model of chronic obstructive pulmonary disease
RU2770364C1 (ru) Способ лечения болезней легких ингаляционным введением мезенхимальных стромальных клеток и гексапептида
CN116033903A (zh) 奎宁及其产生先天免疫应答的用途
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
HK1114567A1 (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241105

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106